AustralieFrV1, PascalFrancis, Corpus, bibRecord, 003B14

Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study

Identifieur interne : 003B14 ( PascalFrancis/Corpus ); précédent : 003B13; suivant : 003B15

Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study

Auteurs : Milena Maule ; Ghislaine Scelo ; Guido Pastore ; Paul Brennan ; Kari Hemminki ; Elizabeth Tracey ; Risto Sankila ; Elisabete Weiderpass ; Jorgen H. Olsen ; Mary L. Mcbride ; David H. Brewster ; Vera Pompe-Kirn ; Erich V. Kliewer ; KEE SENG CHIA ; Jon M. Tonita ; Carmen Martos ; Jon G. Jonasson ; Franco Merletti ; Paolo Boffetta

Source :

Journal of the National Cancer Institute [ 0027-8874 ] ; 2007.

RBID : Pascal:07-0344444

Descripteurs français

Pascal (Inist)
- Second cancer, Facteur risque, Epidémiologie, Leucémie, Homme, Etude multicentrique, Lymphome, Cancérologie, Australie, Canada, Europe, Pays Scandinaves, Singapour, Enfance.

English descriptors

KwdEn :
- Australia, Canada, Cancerology, Epidemiology, Europe, Human, Leukemia, Lymphoma, Multicenter study, Risk factor, Scandinavia, Second cancer, Singapore.

Abstract

Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. We quantified such risk using a large dataset from 13 population-based cancer registries. Methods The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma occurring in children aged 0-14 years and on subsequent second malignant neoplasms for different time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standardized incidence ratios (SIRs) and corresponding 95% confidence intervals (Cls), using the incidence rates in the general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. Results A total of 133 second malignant neoplasms were observed in 16540 patients (12731 leukemias, 1246 Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% Cl = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% Cl = 4.30 to 17.9), and thyroid cancer (nine cases, SIR = 18.8, 95% Cl = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% Cl = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% Cl = 7.66 to 45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% Cl = 12.5 to 74.0); and the most frequent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% Cl = 14.8 to 88.0) and brain cancer (four cases, SIR = 6.97, 95% Cl = 1.90 to 17.9). Cumulative incidence of any second malignant neoplasm was 2.43% (95% Cl = 1.09 to 3.78), 12.7% (95% Cl = 8.29 to 17.2), and 2.50% (95% Cl = 1.04 to 3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, respectively. Conclusions This population-based study provides, to our knowledge, the most precise and up-to-date estimates for relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0027-8874`
A03		`1`		`@0 J. Natl. Cancer Inst.`
A05				`@2 99`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study`
A11	`01`	`1`		`@1 MAULE (Milena)`
A11	`02`	`1`		`@1 SCELO (Ghislaine)`
A11	`03`	`1`		`@1 PASTORE (Guido)`
A11	`04`	`1`		`@1 BRENNAN (Paul)`
A11	`05`	`1`		`@1 HEMMINKI (Kari)`
A11	`06`	`1`		`@1 TRACEY (Elizabeth)`
A11	`07`	`1`		`@1 SANKILA (Risto)`
A11	`08`	`1`		`@1 WEIDERPASS (Elisabete)`
A11	`09`	`1`		`@1 OLSEN (Jorgen H.)`
A11	`10`	`1`		`@1 MCBRIDE (Mary L.)`
A11	`11`	`1`		`@1 BREWSTER (David H.)`
A11	`12`	`1`		`@1 POMPE-KIRN (Vera)`
A11	`13`	`1`		`@1 KLIEWER (Erich V.)`
A11	`14`	`1`		`@1 KEE SENG CHIA`
A11	`15`	`1`		`@1 TONITA (Jon M.)`
A11	`16`	`1`		`@1 MARTOS (Carmen)`
A11	`17`	`1`		`@1 JONASSON (Jon G.)`
A11	`18`	`1`		`@1 MERLETTI (Franco)`
A11	`19`	`1`		`@1 BOFFETTA (Paolo)`
A14	`01`			`@1 Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin @2 Turin @3 ITA @Z 1 aut. @Z 3 aut. @Z 18 aut.`
A14	`02`			`@1 International Agency for Research on Cancer @2 Lyon @3 FRA @Z 2 aut. @Z 4 aut. @Z 19 aut.`
A14	`03`			`@1 Division of Pediatrics, Department of Medical Sciences, University of Eastern Piedmont at Novara @2 Novara @3 ITA @Z 3 aut.`
A14	`04`			`@1 Division of Molecular Genetic Epidemiology, German Cancer Research Center @2 Heidelberg @3 DEU @Z 5 aut.`
A14	`05`			`@1 Center of Family Medicine, Karolinska Institutet @2 Huddinge @3 SWE @Z 5 aut.`
A14	`06`			`@1 New South Wales Cancer Registry @2 Eveleigh, New South Wales @3 AUS @Z 6 aut.`
A14	`07`			`@1 Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research @2 Helsinki @3 FIN @Z 7 aut.`
A14	`08`			`@1 The Cancer Registry of Norway @2 Oslo @3 NOR @Z 8 aut.`
A14	`09`			`@1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet @2 Stockholm @3 SWE @Z 8 aut.`
A14	`10`			`@1 Institute of Cancer Epidemiology, Danish Cancer Society @2 Copenhagen @3 DNK @Z 9 aut.`
A14	`11`			`@1 British Columbia Cancer Agency @2 Vancouver, BC @3 CAN @Z 10 aut.`
A14	`12`			`@1 Scottish Cancer Registry, Information Services Division, NHS National Services Scotland @2 Edinburgh @3 GBR @Z 11 aut.`
A14	`13`			`@1 Cancer Registry of Slovenia, Institute of Oncology @2 Ljubljana @3 SVN @Z 12 aut.`
A14	`14`			`@1 Epidemiology and Cancer Registry, CancerCare Manitoba @2 Winnipeg, MB @3 CAN @Z 13 aut.`
A14	`15`			`@1 Department of Community Health Sciences, University of Manitoba @2 Winnipeg, MB @3 CAN @Z 13 aut.`
A14	`16`			`@1 Center for Molecular Epidemiology @2 Singapore @3 SGP @Z 14 aut.`
A20				`@1 790-800`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3364 @5 354000162294460060`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 60 ref.`
A47	`01`	`1`		`@0 07-0344444`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of the National Cancer Institute`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. We quantified such risk using a large dataset from 13 population-based cancer registries. Methods The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma occurring in children aged 0-14 years and on subsequent second malignant neoplasms for different time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standardized incidence ratios (SIRs) and corresponding 95% confidence intervals (Cls), using the incidence rates in the general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. Results A total of 133 second malignant neoplasms were observed in 16540 patients (12731 leukemias, 1246 Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% Cl = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% Cl = 4.30 to 17.9), and thyroid cancer (nine cases, SIR = 18.8, 95% Cl = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% Cl = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% Cl = 7.66 to 45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% Cl = 12.5 to 74.0); and the most frequent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% Cl = 14.8 to 88.0) and brain cancer (four cases, SIR = 6.97, 95% Cl = 1.90 to 17.9). Cumulative incidence of any second malignant neoplasm was 2.43% (95% Cl = 1.09 to 3.78), 12.7% (95% Cl = 8.29 to 17.2), and 2.50% (95% Cl = 1.04 to 3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, respectively. Conclusions This population-based study provides, to our knowledge, the most precise and up-to-date estimates for relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma.
C02	`01`	`X`		`@0 002B04B`
C02	`02`	`X`		`@0 002B19B`
C02	`03`	`X`		`@0 235`
C03	`01`	`X`	`FRE`	`@0 Second cancer @5 01`
C03	`01`	`X`	`ENG`	`@0 Second cancer @5 01`
C03	`01`	`X`	`SPA`	`@0 Segundo cáncer @5 01`
C03	`02`	`X`	`FRE`	`@0 Facteur risque @5 02`
C03	`02`	`X`	`ENG`	`@0 Risk factor @5 02`
C03	`02`	`X`	`SPA`	`@0 Factor riesgo @5 02`
C03	`03`	`X`	`FRE`	`@0 Epidémiologie @5 03`
C03	`03`	`X`	`ENG`	`@0 Epidemiology @5 03`
C03	`03`	`X`	`SPA`	`@0 Epidemiología @5 03`
C03	`04`	`X`	`FRE`	`@0 Leucémie @5 04`
C03	`04`	`X`	`ENG`	`@0 Leukemia @5 04`
C03	`04`	`X`	`SPA`	`@0 Leucemia @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 05`
C03	`05`	`X`	`ENG`	`@0 Human @5 05`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 05`
C03	`06`	`X`	`FRE`	`@0 Etude multicentrique @5 06`
C03	`06`	`X`	`ENG`	`@0 Multicenter study @5 06`
C03	`06`	`X`	`SPA`	`@0 Estudio multicéntrico @5 06`
C03	`07`	`X`	`FRE`	`@0 Lymphome @5 07`
C03	`07`	`X`	`ENG`	`@0 Lymphoma @5 07`
C03	`07`	`X`	`SPA`	`@0 Linfoma @5 07`
C03	`08`	`X`	`FRE`	`@0 Cancérologie @5 08`
C03	`08`	`X`	`ENG`	`@0 Cancerology @5 08`
C03	`08`	`X`	`SPA`	`@0 Cancerología @5 08`
C03	`09`	`X`	`FRE`	`@0 Australie @2 NG @5 09`
C03	`09`	`X`	`ENG`	`@0 Australia @2 NG @5 09`
C03	`09`	`X`	`SPA`	`@0 Australia @2 NG @5 09`
C03	`10`	`X`	`FRE`	`@0 Canada @2 NG @5 11`
C03	`10`	`X`	`ENG`	`@0 Canada @2 NG @5 11`
C03	`10`	`X`	`SPA`	`@0 Canadá @2 NG @5 11`
C03	`11`	`X`	`FRE`	`@0 Europe @2 NG @5 12`
C03	`11`	`X`	`ENG`	`@0 Europe @2 NG @5 12`
C03	`11`	`X`	`SPA`	`@0 Europa @2 NG @5 12`
C03	`12`	`X`	`FRE`	`@0 Pays Scandinaves @2 NG @5 17`
C03	`12`	`X`	`ENG`	`@0 Scandinavia @2 NG @5 17`
C03	`12`	`X`	`SPA`	`@0 Países escandinavos @2 NG @5 17`
C03	`13`	`X`	`FRE`	`@0 Singapour @2 NG @5 18`
C03	`13`	`X`	`ENG`	`@0 Singapore @2 NG @5 18`
C03	`13`	`X`	`SPA`	`@0 Singapur @2 NG @5 18`
C03	`14`	`X`	`FRE`	`@0 Enfance @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Océanie @2 NG`
C07	`01`	`X`	`ENG`	`@0 Oceania @2 NG`
C07	`01`	`X`	`SPA`	`@0 Oceania @2 NG`
C07	`02`	`X`	`FRE`	`@0 Amérique du Nord @2 NG`
C07	`02`	`X`	`ENG`	`@0 North America @2 NG`
C07	`02`	`X`	`SPA`	`@0 America del norte @2 NG`
C07	`03`	`X`	`FRE`	`@0 Amérique @2 NG`
C07	`03`	`X`	`ENG`	`@0 America @2 NG`
C07	`03`	`X`	`SPA`	`@0 America @2 NG`
C07	`04`	`X`	`FRE`	`@0 Asie @2 NG`
C07	`04`	`X`	`ENG`	`@0 Asia @2 NG`
C07	`04`	`X`	`SPA`	`@0 Asia @2 NG`
C07	`05`	`X`	`FRE`	`@0 Tumeur maligne @5 37`
C07	`05`	`X`	`ENG`	`@0 Malignant tumor @5 37`
C07	`05`	`X`	`SPA`	`@0 Tumor maligno @5 37`
C07	`06`	`X`	`FRE`	`@0 Hémopathie maligne @5 38`
C07	`06`	`X`	`ENG`	`@0 Malignant hemopathy @5 38`
C07	`06`	`X`	`SPA`	`@0 Hemopatía maligna @5 38`
C07	`07`	`X`	`FRE`	`@0 Lymphoprolifératif syndrome @5 39`
C07	`07`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @5 39`
C07	`07`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @5 39`
C07	`08`	`X`	`FRE`	`@0 Santé publique @5 40`
C07	`08`	`X`	`ENG`	`@0 Public health @5 40`
C07	`08`	`X`	`SPA`	`@0 Salud pública @5 40`
C07	`09`	`X`	`FRE`	`@0 Hémopathie maligne lymphoïde @4 CD @5 96`
C07	`09`	`X`	`ENG`	`@0 Lymphoid neoplasm @4 CD @5 96`
N21				`@1 218`

Format Inist (serveur)

NO :	PASCAL 07-0344444 INIST
ET :	Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study
AU :	MAULE (Milena); SCELO (Ghislaine); PASTORE (Guido); BRENNAN (Paul); HEMMINKI (Kari); TRACEY (Elizabeth); SANKILA (Risto); WEIDERPASS (Elisabete); OLSEN (Jorgen H.); MCBRIDE (Mary L.); BREWSTER (David H.); POMPE-KIRN (Vera); KLIEWER (Erich V.); KEE SENG CHIA; TONITA (Jon M.); MARTOS (Carmen); JONASSON (Jon G.); MERLETTI (Franco); BOFFETTA (Paolo)
AF :	Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin/Turin/Italie (1 aut., 3 aut., 18 aut.); International Agency for Research on Cancer/Lyon/France (2 aut., 4 aut., 19 aut.); Division of Pediatrics, Department of Medical Sciences, University of Eastern Piedmont at Novara/Novara/Italie (3 aut.); Division of Molecular Genetic Epidemiology, German Cancer Research Center/Heidelberg/Allemagne (5 aut.); Center of Family Medicine, Karolinska Institutet/Huddinge/Suède (5 aut.); New South Wales Cancer Registry/Eveleigh, New South Wales/Australie (6 aut.); Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research/Helsinki/Finlande (7 aut.); The Cancer Registry of Norway/Oslo/Norvège (8 aut.); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet/Stockholm/Suède (8 aut.); Institute of Cancer Epidemiology, Danish Cancer Society/Copenhagen/Danemark (9 aut.); British Columbia Cancer Agency/Vancouver, BC/Canada (10 aut.); Scottish Cancer Registry, Information Services Division, NHS National Services Scotland/Edinburgh/Royaume-Uni (11 aut.); Cancer Registry of Slovenia, Institute of Oncology/Ljubljana/Slovénie (12 aut.); Epidemiology and Cancer Registry, CancerCare Manitoba/Winnipeg, MB/Canada (13 aut.); Department of Community Health Sciences, University of Manitoba/Winnipeg, MB/Canada (13 aut.); Center for Molecular Epidemiology/Singapore/Singapour (14 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of the National Cancer Institute; ISSN 0027-8874; Etats-Unis; Da. 2007; Vol. 99; No. 10; Pp. 790-800; Bibl. 60 ref.
LA :	Anglais
EA :	Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. We quantified such risk using a large dataset from 13 population-based cancer registries. Methods The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma occurring in children aged 0-14 years and on subsequent second malignant neoplasms for different time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standardized incidence ratios (SIRs) and corresponding 95% confidence intervals (Cls), using the incidence rates in the general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. Results A total of 133 second malignant neoplasms were observed in 16540 patients (12731 leukemias, 1246 Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% Cl = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% Cl = 4.30 to 17.9), and thyroid cancer (nine cases, SIR = 18.8, 95% Cl = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% Cl = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% Cl = 7.66 to 45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% Cl = 12.5 to 74.0); and the most frequent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% Cl = 14.8 to 88.0) and brain cancer (four cases, SIR = 6.97, 95% Cl = 1.90 to 17.9). Cumulative incidence of any second malignant neoplasm was 2.43% (95% Cl = 1.09 to 3.78), 12.7% (95% Cl = 8.29 to 17.2), and 2.50% (95% Cl = 1.04 to 3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, respectively. Conclusions This population-based study provides, to our knowledge, the most precise and up-to-date estimates for relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma.
CC :	002B04B; 002B19B; 235
FD :	Second cancer; Facteur risque; Epidémiologie; Leucémie; Homme; Etude multicentrique; Lymphome; Cancérologie; Australie; Canada; Europe; Pays Scandinaves; Singapour; Enfance
FG :	Océanie; Amérique du Nord; Amérique; Asie; Tumeur maligne; Hémopathie maligne; Lymphoprolifératif syndrome; Santé publique; Hémopathie maligne lymphoïde
ED :	Second cancer; Risk factor; Epidemiology; Leukemia; Human; Multicenter study; Lymphoma; Cancerology; Australia; Canada; Europe; Scandinavia; Singapore
EG :	Oceania; North America; America; Asia; Malignant tumor; Malignant hemopathy; Lymphoproliferative syndrome; Public health; Lymphoid neoplasm
SD :	Segundo cáncer; Factor riesgo; Epidemiología; Leucemia; Hombre; Estudio multicéntrico; Linfoma; Cancerología; Australia; Canadá; Europa; Países escandinavos; Singapur
LO :	INIST-3364.354000162294460060
ID :	07-0344444

Links to Exploration step

Pascal:07-0344444

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study</title>
<author><name sortKey="Maule, Milena" sort="Maule, Milena" uniqKey="Maule M" first="Milena" last="Maule">Milena Maule</name>
<affiliation><inist:fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scelo, Ghislaine" sort="Scelo, Ghislaine" uniqKey="Scelo G" first="Ghislaine" last="Scelo">Ghislaine Scelo</name>
<affiliation><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pastore, Guido" sort="Pastore, Guido" uniqKey="Pastore G" first="Guido" last="Pastore">Guido Pastore</name>
<affiliation><inist:fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Division of Pediatrics, Department of Medical Sciences, University of Eastern Piedmont at Novara</s1>
<s2>Novara</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brennan, Paul" sort="Brennan, Paul" uniqKey="Brennan P" first="Paul" last="Brennan">Paul Brennan</name>
<affiliation><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hemminki, Kari" sort="Hemminki, Kari" uniqKey="Hemminki K" first="Kari" last="Hemminki">Kari Hemminki</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Molecular Genetic Epidemiology, German Cancer Research Center</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Center of Family Medicine, Karolinska Institutet</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tracey, Elizabeth" sort="Tracey, Elizabeth" uniqKey="Tracey E" first="Elizabeth" last="Tracey">Elizabeth Tracey</name>
<affiliation><inist:fA14 i1="06"><s1>New South Wales Cancer Registry</s1>
<s2>Eveleigh, New South Wales</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sankila, Risto" sort="Sankila, Risto" uniqKey="Sankila R" first="Risto" last="Sankila">Risto Sankila</name>
<affiliation><inist:fA14 i1="07"><s1>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weiderpass, Elisabete" sort="Weiderpass, Elisabete" uniqKey="Weiderpass E" first="Elisabete" last="Weiderpass">Elisabete Weiderpass</name>
<affiliation><inist:fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olsen, Jorgen H" sort="Olsen, Jorgen H" uniqKey="Olsen J" first="Jorgen H." last="Olsen">Jorgen H. Olsen</name>
<affiliation><inist:fA14 i1="10"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcbride, Mary L" sort="Mcbride, Mary L" uniqKey="Mcbride M" first="Mary L." last="Mcbride">Mary L. Mcbride</name>
<affiliation><inist:fA14 i1="11"><s1>British Columbia Cancer Agency</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brewster, David H" sort="Brewster, David H" uniqKey="Brewster D" first="David H." last="Brewster">David H. Brewster</name>
<affiliation><inist:fA14 i1="12"><s1>Scottish Cancer Registry, Information Services Division, NHS National Services Scotland</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pompe Kirn, Vera" sort="Pompe Kirn, Vera" uniqKey="Pompe Kirn V" first="Vera" last="Pompe-Kirn">Vera Pompe-Kirn</name>
<affiliation><inist:fA14 i1="13"><s1>Cancer Registry of Slovenia, Institute of Oncology</s1>
<s2>Ljubljana</s2>
<s3>SVN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kliewer, Erich V" sort="Kliewer, Erich V" uniqKey="Kliewer E" first="Erich V." last="Kliewer">Erich V. Kliewer</name>
<affiliation><inist:fA14 i1="14"><s1>Epidemiology and Cancer Registry, CancerCare Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="15"><s1>Department of Community Health Sciences, University of Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kee Seng Chia" sort="Kee Seng Chia" uniqKey="Kee Seng Chia" last="Kee Seng Chia">KEE SENG CHIA</name>
<affiliation><inist:fA14 i1="16"><s1>Center for Molecular Epidemiology</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tonita, Jon M" sort="Tonita, Jon M" uniqKey="Tonita J" first="Jon M." last="Tonita">Jon M. Tonita</name>
</author>
<author><name sortKey="Martos, Carmen" sort="Martos, Carmen" uniqKey="Martos C" first="Carmen" last="Martos">Carmen Martos</name>
</author>
<author><name sortKey="Jonasson, Jon G" sort="Jonasson, Jon G" uniqKey="Jonasson J" first="Jon G." last="Jonasson">Jon G. Jonasson</name>
</author>
<author><name sortKey="Merletti, Franco" sort="Merletti, Franco" uniqKey="Merletti F" first="Franco" last="Merletti">Franco Merletti</name>
<affiliation><inist:fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0344444</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0344444 INIST</idno>
<idno type="RBID">Pascal:07-0344444</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003B14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study</title>
<author><name sortKey="Maule, Milena" sort="Maule, Milena" uniqKey="Maule M" first="Milena" last="Maule">Milena Maule</name>
<affiliation><inist:fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scelo, Ghislaine" sort="Scelo, Ghislaine" uniqKey="Scelo G" first="Ghislaine" last="Scelo">Ghislaine Scelo</name>
<affiliation><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pastore, Guido" sort="Pastore, Guido" uniqKey="Pastore G" first="Guido" last="Pastore">Guido Pastore</name>
<affiliation><inist:fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Division of Pediatrics, Department of Medical Sciences, University of Eastern Piedmont at Novara</s1>
<s2>Novara</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brennan, Paul" sort="Brennan, Paul" uniqKey="Brennan P" first="Paul" last="Brennan">Paul Brennan</name>
<affiliation><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hemminki, Kari" sort="Hemminki, Kari" uniqKey="Hemminki K" first="Kari" last="Hemminki">Kari Hemminki</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Molecular Genetic Epidemiology, German Cancer Research Center</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Center of Family Medicine, Karolinska Institutet</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tracey, Elizabeth" sort="Tracey, Elizabeth" uniqKey="Tracey E" first="Elizabeth" last="Tracey">Elizabeth Tracey</name>
<affiliation><inist:fA14 i1="06"><s1>New South Wales Cancer Registry</s1>
<s2>Eveleigh, New South Wales</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sankila, Risto" sort="Sankila, Risto" uniqKey="Sankila R" first="Risto" last="Sankila">Risto Sankila</name>
<affiliation><inist:fA14 i1="07"><s1>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weiderpass, Elisabete" sort="Weiderpass, Elisabete" uniqKey="Weiderpass E" first="Elisabete" last="Weiderpass">Elisabete Weiderpass</name>
<affiliation><inist:fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olsen, Jorgen H" sort="Olsen, Jorgen H" uniqKey="Olsen J" first="Jorgen H." last="Olsen">Jorgen H. Olsen</name>
<affiliation><inist:fA14 i1="10"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcbride, Mary L" sort="Mcbride, Mary L" uniqKey="Mcbride M" first="Mary L." last="Mcbride">Mary L. Mcbride</name>
<affiliation><inist:fA14 i1="11"><s1>British Columbia Cancer Agency</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brewster, David H" sort="Brewster, David H" uniqKey="Brewster D" first="David H." last="Brewster">David H. Brewster</name>
<affiliation><inist:fA14 i1="12"><s1>Scottish Cancer Registry, Information Services Division, NHS National Services Scotland</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pompe Kirn, Vera" sort="Pompe Kirn, Vera" uniqKey="Pompe Kirn V" first="Vera" last="Pompe-Kirn">Vera Pompe-Kirn</name>
<affiliation><inist:fA14 i1="13"><s1>Cancer Registry of Slovenia, Institute of Oncology</s1>
<s2>Ljubljana</s2>
<s3>SVN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kliewer, Erich V" sort="Kliewer, Erich V" uniqKey="Kliewer E" first="Erich V." last="Kliewer">Erich V. Kliewer</name>
<affiliation><inist:fA14 i1="14"><s1>Epidemiology and Cancer Registry, CancerCare Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="15"><s1>Department of Community Health Sciences, University of Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kee Seng Chia" sort="Kee Seng Chia" uniqKey="Kee Seng Chia" last="Kee Seng Chia">KEE SENG CHIA</name>
<affiliation><inist:fA14 i1="16"><s1>Center for Molecular Epidemiology</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tonita, Jon M" sort="Tonita, Jon M" uniqKey="Tonita J" first="Jon M." last="Tonita">Jon M. Tonita</name>
</author>
<author><name sortKey="Martos, Carmen" sort="Martos, Carmen" uniqKey="Martos C" first="Carmen" last="Martos">Carmen Martos</name>
</author>
<author><name sortKey="Jonasson, Jon G" sort="Jonasson, Jon G" uniqKey="Jonasson J" first="Jon G." last="Jonasson">Jon G. Jonasson</name>
</author>
<author><name sortKey="Merletti, Franco" sort="Merletti, Franco" uniqKey="Merletti F" first="Franco" last="Merletti">Franco Merletti</name>
<affiliation><inist:fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation><inist:fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the National Cancer Institute</title>
<title level="j" type="abbreviated">J. Natl. Cancer Inst.</title>
<idno type="ISSN">0027-8874</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the National Cancer Institute</title>
<title level="j" type="abbreviated">J. Natl. Cancer Inst.</title>
<idno type="ISSN">0027-8874</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Australia</term>
<term>Canada</term>
<term>Cancerology</term>
<term>Epidemiology</term>
<term>Europe</term>
<term>Human</term>
<term>Leukemia</term>
<term>Lymphoma</term>
<term>Multicenter study</term>
<term>Risk factor</term>
<term>Scandinavia</term>
<term>Second cancer</term>
<term>Singapore</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Second cancer</term>
<term>Facteur risque</term>
<term>Epidémiologie</term>
<term>Leucémie</term>
<term>Homme</term>
<term>Etude multicentrique</term>
<term>Lymphome</term>
<term>Cancérologie</term>
<term>Australie</term>
<term>Canada</term>
<term>Europe</term>
<term>Pays Scandinaves</term>
<term>Singapour</term>
<term>Enfance</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. We quantified such risk using a large dataset from 13 population-based cancer registries. Methods The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma occurring in children aged 0-14 years and on subsequent second malignant neoplasms for different time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standardized incidence ratios (SIRs) and corresponding 95% confidence intervals (Cls), using the incidence rates in the general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. Results A total of 133 second malignant neoplasms were observed in 16540 patients (12731 leukemias, 1246 Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% Cl = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% Cl = 4.30 to 17.9), and thyroid cancer (nine cases, SIR = 18.8, 95% Cl = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% Cl = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% Cl = 7.66 to 45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% Cl = 12.5 to 74.0); and the most frequent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% Cl = 14.8 to 88.0) and brain cancer (four cases, SIR = 6.97, 95% Cl = 1.90 to 17.9). Cumulative incidence of any second malignant neoplasm was 2.43% (95% Cl = 1.09 to 3.78), 12.7% (95% Cl = 8.29 to 17.2), and 2.50% (95% Cl = 1.04 to 3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, respectively. Conclusions This population-based study provides, to our knowledge, the most precise and up-to-date estimates for relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0027-8874</s0>
</fA01>
<fA03 i2="1"><s0>J. Natl. Cancer Inst.</s0>
</fA03>
<fA05><s2>99</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MAULE (Milena)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SCELO (Ghislaine)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PASTORE (Guido)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BRENNAN (Paul)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HEMMINKI (Kari)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TRACEY (Elizabeth)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SANKILA (Risto)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WEIDERPASS (Elisabete)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>OLSEN (Jorgen H.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MCBRIDE (Mary L.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BREWSTER (David H.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>POMPE-KIRN (Vera)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>KLIEWER (Erich V.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>KEE SENG CHIA</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>TONITA (Jon M.)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>MARTOS (Carmen)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>JONASSON (Jon G.)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>MERLETTI (Franco)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>BOFFETTA (Paolo)</s1>
</fA11>
<fA14 i1="01"><s1>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Pediatrics, Department of Medical Sciences, University of Eastern Piedmont at Novara</s1>
<s2>Novara</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Molecular Genetic Epidemiology, German Cancer Research Center</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Center of Family Medicine, Karolinska Institutet</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>New South Wales Cancer Registry</s1>
<s2>Eveleigh, New South Wales</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Institute of Cancer Epidemiology, Danish Cancer Society</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>British Columbia Cancer Agency</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Scottish Cancer Registry, Information Services Division, NHS National Services Scotland</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Cancer Registry of Slovenia, Institute of Oncology</s1>
<s2>Ljubljana</s2>
<s3>SVN</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Epidemiology and Cancer Registry, CancerCare Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Department of Community Health Sciences, University of Manitoba</s1>
<s2>Winnipeg, MB</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Center for Molecular Epidemiology</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA20><s1>790-800</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3364</s2>
<s5>354000162294460060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>60 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0344444</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of the National Cancer Institute</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. We quantified such risk using a large dataset from 13 population-based cancer registries. Methods The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma occurring in children aged 0-14 years and on subsequent second malignant neoplasms for different time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standardized incidence ratios (SIRs) and corresponding 95% confidence intervals (Cls), using the incidence rates in the general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. Results A total of 133 second malignant neoplasms were observed in 16540 patients (12731 leukemias, 1246 Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% Cl = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% Cl = 4.30 to 17.9), and thyroid cancer (nine cases, SIR = 18.8, 95% Cl = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% Cl = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% Cl = 7.66 to 45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% Cl = 12.5 to 74.0); and the most frequent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% Cl = 14.8 to 88.0) and brain cancer (four cases, SIR = 6.97, 95% Cl = 1.90 to 17.9). Cumulative incidence of any second malignant neoplasm was 2.43% (95% Cl = 1.09 to 3.78), 12.7% (95% Cl = 8.29 to 17.2), and 2.50% (95% Cl = 1.04 to 3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, respectively. Conclusions This population-based study provides, to our knowledge, the most precise and up-to-date estimates for relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04B</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B19B</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>235</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Second cancer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Second cancer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Segundo cáncer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Leucémie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Leukemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Leucemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lymphome</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Lymphoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Linfoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Australie</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Australia</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Australia</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Canada</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Canada</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Canadá</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Pays Scandinaves</s0>
<s2>NG</s2>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Scandinavia</s0>
<s2>NG</s2>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Países escandinavos</s0>
<s2>NG</s2>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Singapour</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Singapore</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Singapur</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Enfance</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Océanie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oceania</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oceania</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Lymphoprolifératif syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Public health</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>96</s5>
</fC07>
<fN21><s1>218</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 07-0344444 INIST</NO>
<ET>Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study</ET>
<AU>MAULE (Milena); SCELO (Ghislaine); PASTORE (Guido); BRENNAN (Paul); HEMMINKI (Kari); TRACEY (Elizabeth); SANKILA (Risto); WEIDERPASS (Elisabete); OLSEN (Jorgen H.); MCBRIDE (Mary L.); BREWSTER (David H.); POMPE-KIRN (Vera); KLIEWER (Erich V.); KEE SENG CHIA; TONITA (Jon M.); MARTOS (Carmen); JONASSON (Jon G.); MERLETTI (Franco); BOFFETTA (Paolo)</AU>
<AF>Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte, Centro di Ricerca in Medicina Sperimentale, University of Turin/Turin/Italie (1 aut., 3 aut., 18 aut.); International Agency for Research on Cancer/Lyon/France (2 aut., 4 aut., 19 aut.); Division of Pediatrics, Department of Medical Sciences, University of Eastern Piedmont at Novara/Novara/Italie (3 aut.); Division of Molecular Genetic Epidemiology, German Cancer Research Center/Heidelberg/Allemagne (5 aut.); Center of Family Medicine, Karolinska Institutet/Huddinge/Suède (5 aut.); New South Wales Cancer Registry/Eveleigh, New South Wales/Australie (6 aut.); Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research/Helsinki/Finlande (7 aut.); The Cancer Registry of Norway/Oslo/Norvège (8 aut.); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet/Stockholm/Suède (8 aut.); Institute of Cancer Epidemiology, Danish Cancer Society/Copenhagen/Danemark (9 aut.); British Columbia Cancer Agency/Vancouver, BC/Canada (10 aut.); Scottish Cancer Registry, Information Services Division, NHS National Services Scotland/Edinburgh/Royaume-Uni (11 aut.); Cancer Registry of Slovenia, Institute of Oncology/Ljubljana/Slovénie (12 aut.); Epidemiology and Cancer Registry, CancerCare Manitoba/Winnipeg, MB/Canada (13 aut.); Department of Community Health Sciences, University of Manitoba/Winnipeg, MB/Canada (13 aut.); Center for Molecular Epidemiology/Singapore/Singapour (14 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of the National Cancer Institute; ISSN 0027-8874; Etats-Unis; Da. 2007; Vol. 99; No. 10; Pp. 790-800; Bibl. 60 ref.</SO>
<LA>Anglais</LA>
<EA>Background Survivors of childhood leukemia and lymphoma experience high risks of second malignant neoplasms. We quantified such risk using a large dataset from 13 population-based cancer registries. Methods The registries provided individual data on cases of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma occurring in children aged 0-14 years and on subsequent second malignant neoplasms for different time periods from 1943 to 2000. Risks of second malignant neoplasms were assessed through standardized incidence ratios (SIRs) and corresponding 95% confidence intervals (Cls), using the incidence rates in the general populations covered by the registries as a reference. Cumulative absolute risks were also calculated. Results A total of 133 second malignant neoplasms were observed in 16540 patients (12731 leukemias, 1246 Hodgkin lymphomas, and 2563 non-Hodgkin lymphomas) after an average follow-up of 6.5 years. The most frequent second malignancies after leukemia were brain cancer (19 cases, SIR = 8.52, 95% Cl = 5.13 to 13.3), non-Hodgkin lymphoma (nine cases, SIR = 9.41, 95% Cl = 4.30 to 17.9), and thyroid cancer (nine cases, SIR = 18.8, 95% Cl = 8.60 to 35.7); the most frequent after Hodgkin lymphoma were thyroid cancer (nine cases, SIR = 52.5, 95% Cl = 24.0 to 99.6), breast cancer (six cases, SIR = 20.9, 95% Cl = 7.66 to 45.4), and neoplasms of skin (non-melanoma) (six cases, SIR = 34.0, 95% Cl = 12.5 to 74.0); and the most frequent after non-Hodgkin lymphoma were thyroid cancer (six cases, SIR = 40.4, 95% Cl = 14.8 to 88.0) and brain cancer (four cases, SIR = 6.97, 95% Cl = 1.90 to 17.9). Cumulative incidence of any second malignant neoplasm was 2.43% (95% Cl = 1.09 to 3.78), 12.7% (95% Cl = 8.29 to 17.2), and 2.50% (95% Cl = 1.04 to 3.96) within 30 years from diagnosis of leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, respectively. Conclusions This population-based study provides, to our knowledge, the most precise and up-to-date estimates for relative and absolute risks of second malignant neoplasms after childhood leukemia and lymphoma.</EA>
<CC>002B04B; 002B19B; 235</CC>
<FD>Second cancer; Facteur risque; Epidémiologie; Leucémie; Homme; Etude multicentrique; Lymphome; Cancérologie; Australie; Canada; Europe; Pays Scandinaves; Singapour; Enfance</FD>
<FG>Océanie; Amérique du Nord; Amérique; Asie; Tumeur maligne; Hémopathie maligne; Lymphoprolifératif syndrome; Santé publique; Hémopathie maligne lymphoïde</FG>
<ED>Second cancer; Risk factor; Epidemiology; Leukemia; Human; Multicenter study; Lymphoma; Cancerology; Australia; Canada; Europe; Scandinavia; Singapore</ED>
<EG>Oceania; North America; America; Asia; Malignant tumor; Malignant hemopathy; Lymphoproliferative syndrome; Public health; Lymphoid neoplasm</EG>
<SD>Segundo cáncer; Factor riesgo; Epidemiología; Leucemia; Hombre; Estudio multicéntrico; Linfoma; Cancerología; Australia; Canadá; Europa; Países escandinavos; Singapur</SD>
<LO>INIST-3364.354000162294460060</LO>
<ID>07-0344444</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B14 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003B14 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0344444
   |texte=   Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study

Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri